ETF Securities launches CURE ETF
ETF Securities has launched its new CURE exchange-traded fund (ETF) on the Australian Securities Exchange (ASX), which will offer investors exposure to healthcare biotechnology companies.
CURE would follow the S&P Biotechnology Select Industry Index, which according to the company, achieved annual growth of 21.9 per cent in Australian dollar terms over the five years to 31 October 2018.
Additionally, the fund would hold more than 120 biotechnology firms in its portfolio, with a focus on small and mid-cap companies. The fund’s fee would stand at 0.45 per cent.
Head of ETF Securities Australia, Kris Walesby, said: “This is very much a high growth-oriented product.”
“Given the mainly mid- and small-cap profiles of the constituent stocks, we’d expect to see profitable M&A activity. We are pleased to be adding CURE to our ‘Future Present’ series of ETFs.”
Walesby also stressed that there would be demanding filters to be met before a company can be included in CURE, with companies needing to meet S&P Dow Jones Indices’ Float Adjustment liquidity requirements.
AUTHOR
Oksana Patron
Recommended for you
Several wealth management companies have been shortlisted in the second annual Australian AI Awards program, which champions individuals and organisations pioneering Australian AI innovation.
Women are expected to inherit US$124 trillion through the intergenerational wealth transfer, but Capital Group has found they are twice as likely to rely on social media for advice over a financial adviser.
Challenger Investment Management has raised $350 million during the offer period for its new ASX-listed investment structure.
A week after Lonsec downgraded multiple funds from Metrics Credit Partners, rival research house Zenith Investment Partners has opted to retain its ratings for the same funds.
